Abstract: The present disclosure generally relates to compositions and methods to reduce the biological age and/or reduce the rate of increase of the biological age of an adult animal. More specifically, the present disclosure relates to administering a formulation comprising an effective amount of glycine and/or functional derivatives, alone or in combination with a dietary regime such as caloric restriction, senior diet or low protein diet. The formulation can concomitantly reduce the biological age of a tissue, organ or physiological system in the adult animal in need; or treat, prevent, or delay the onset of an organ disease, or decline of organ function, or condition relating thereto in an adult animal in need.

Abstract: The present disclosure generally relates to compositions and methods to reduce the biological age and/or reduce the rate of increase of the biological age of an adult animal. More specifically, the present disclosure relates to administering a formulation comprising an effective amount of thymol and/or carvacrol, alone or in combination with a dietary regime such as caloric restriction, senior diet or low protein diet. The formulation can concomitantly reduce the biological age of a tissue, organ or physiological system in the adult animal in need; or treat, prevent, or delay the onset of an organ disease, or decline of organ function, or condition relating thereto in an adult animal in need.

Abstract: The present invention provides a method of determining whether a canine subject has or is at a risk of developing osteoarthritis (OA), the method comprising: a) providing a DNA methylation profile from a sample obtained from the canine subject; and b) determining whether the canine subject has or is at risk of developing OA by comparing at least part of the DNA methylation profile to a reference DNA methylation profile.

Abstract: The present invention for selecting a lifestyle regime, dietary regime or therapeutic intervention for a dog, the method comprising: a) providing a DNA methylation profile from a sample obtained from the dog; b) determining a biological age of the dog using the DNA methylation profile; and c) selecting a suitable lifestyle regime, dietary regime or therapeutic intervention for the dog based on the biological age determined in step b).

Abstract: The present invention relates to a method for determining a mortality risk and/or probability of a healthy lifespan of a dog; said method comprising determining the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and/or red blood cell count.

Abstract: The present invention provides a method for determining a mortality risk and/or probability of healthy lifespan of a cat; said method comprising determining the level of one or more biomarker(s) in one or more samples obtained from the cat, wherein the one or more biomarker(s) is selected from white blood cell count, haemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, and/or serum GGT.

Abstract: A method for generating a biological clock including a DNA methylation profile which is suitable for use with at least two different sample types, the method includes: (i) providing a first set of DNA methylation profiles generated from the at least two different sample types from a plurality of subjects; (ii) generating a composite DNA methylation profile from the first set of DNA methylation profiles, wherein the composite DNA methylation profile comprises methylation sites that have a matched status in the different sample types; and (iii) using the composite DNA methylation profile to generate a biological clock using reference DNA methylation profiles from one of the at least two sample types.

Abstract: A method for determining a mortality risk and/or probability of a healthy lifespan of a dog, the method including a) providing a DNA methylation profile from a sample obtained from the dog; and b) determining a mortality risk and/or probability of a healthy lifespan for the dog using the DNA methylation profile. The DNA methylation profile contains at least one methylation site as listed in Table 3.

Abstract: The present invention provides a method for determining a mortality risk and/or probability of a healthy lifespan of a dog; said method comprising a) providing a DNA methylation profile from a sample obtained from the dog; and b) determining a mortality risk and/or probability of a healthy lifespan for the dog using the DNA methylation profile; wherein the DNA methylation profile comprises at least one methylation site as listed in Table 1.

Abstract: The present invention relates to a method of determining the contribution of a dog breed to a test dog genome, comprising: a) providing a DNA methylation profile from a sample obtained from the test dog; and b) determining the contribution of a dog breed to the test dog genome by comparing at least part of the DNA methylation profile of the test dog to reference DNA methylation profiles from different dog breeds.

Abstract: A nutritional composition comprising miR-3141. miR-3141 or said nutritional composition for use as a medicament. Use of miR-3141 to modulate gene expression of one or more geneselected from Claudin 2 and SLC2A1. A method of producing said nutritional composition.

Abstract: A nutritional composition comprising miR-3126. miR-3126 or said nutritional composition for use as a medicament. Use of miR-3126 to modulate gene expression of one or more gene selected from: Ninein, Unc-13 homolog D, Sulfatase 2, IL-32, OXER1, TMEM127, Butyrophilin, Integrin subunit alpha 2, Integrin beta 1, tubulin alpha 4A, tubulin beta 6, tubulin beta 2A and tubulin beta 2B. A method of producing said nutritional composition.

Abstract: A nutritional composition comprising miR-3184. miR-3184 or said nutritional composition for use as a medicament. Use of miR-3184 to modulate gene expression of one or more gene selected from Lipin 2 or Insulin Like Growth Factor 2. A method of producing said nutritional composition.